Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study
Zheng Quan Toh, Fiona M Russell, Rita Reyburn, James Fong, Evelyn Tuivaga, Tupou Ratu, Cattram D Nguyen, Rachel Devi, Mike Kama, Silivia Matanitobua, Sepehr N Tabrizi, Suzanne M Garland, Rohit Sinha, Ian Frazer, Lisi Tikoduadua, Joseph Kado, Eric Rafai, Edward K Mulholland, Paul V Licciardi
CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2017
BACKGROUND: The duration of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been determined. We compared the antibody responses in girls previously vaccinated with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously. METHODS: A prospective cohort study was undertaken in 200 Fijian girls 15-19 years of age. Approximately equal numbers of girls from 2 main ethnic groups (Fijians of Indian descent [FID] and Indigenous Fijians [iTaukei]) in Fiji were recruited for each dosage groups. Blood was drawn before and 28 days following a single dose of bivalent HPV vaccine (2vHPV; Cervarix, GlaxoSmithKline). We measured neut..View full abstract
This work was supported by the Department of Foreign Affairs and Trade of the Australian government and the Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by ABT Associates on behalf of the Australian government. This work was also supported in part by the Victorian government's Operational Infrastructure Support Program. Z. Q. T. is a recipient of the Melbourne Research Scholarship from the University of Melbourne. F. M. R. is a recipient of National Health and Medical Research Council Early Career Fellowship.